Harrow (HROW)

Harrow’s commercial portfolio includes branded ophthalmic products used across areas such as cataract surgery, dry eye disease, inflammation, infection, corneal disease, glaucoma, and retinal care. Its brands include Iheezo, Vevye, Natacyn, Maxitrol, Maxidex, Byooviz, and Opuviz, among others. The company’s strategy combines direct commercialisation with product licensing and acquisition, allowing it to build a broader eye-care platform rather than relying on a single medicine.

The company also operates ImprimisRx, a compounding and ophthalmology-focused pharmacy business that has historically connected Harrow with U.S. eye-care practices. Its reportable segments include Branded, which generates the majority of revenue, and ImprimisRx. This structure gives Harrow both a branded pharmaceutical growth engine and a service-oriented channel tied to clinical practice needs.

Harrow’s development pipeline includes candidates such as MELT-300, H-N08, CR-01, and MELT-210, which are intended to address unmet needs in ophthalmology and selected adjacent markets. For investors, HROW represents exposure to a niche pharmaceutical company with a concentrated focus on eye care, a growing branded product portfolio, and a business model shaped by relationships with specialist physicians and surgical providers.